| Experience with regorafenib in the treatment of hepatocellular carcinoma A Granito, A Forgione, S Marinelli, M Renzulli, L Ielasi, V Sansone, ... Therapeutic Advances in Gastroenterology 14, 17562848211016959, 2021 | 117 | 2021 |
| TKIs in combination with immunotherapy for hepatocellular carcinoma B Stefanini, L Ielasi, R Chen, C Abbati, M Tonnini, F Tovoli, A Granito Expert review of anticancer therapy 23 (3), 279-291, 2023 | 91 | 2023 |
| Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients F Tovoli, L Ielasi, A Casadei-Gardini, A Granito, FG Foschi, G Rovesti, ... Journal of hepatology 71 (6), 1175-1183, 2019 | 79 | 2019 |
| Treatment of combined hepatocellular and cholangiocarcinoma S Leoni, V Sansone, S De Lorenzo, L Ielasi, F Tovoli, M Renzulli, ... Cancers 12 (4), 794, 2020 | 47 | 2020 |
| Prognostic role of blood eosinophil count in patients with sorafenib-treated hepatocellular carcinoma G Orsi, F Tovoli, V Dadduzio, C Vivaldi, O Brunetti, L Ielasi, F Conti, ... Targeted Oncology 15, 773-785, 2020 | 18 | 2020 |
| Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter … A Casadei-Gardini, G Marisi, V Dadduzio, L Gramantieri, L Faloppi, P Ulivi, ... Clinical Cancer Research 26 (17), 4485-4493, 2020 | 17 | 2020 |
| Beneficial prognostic effects of aspirin in patients receiving sorafenib for hepatocellular carcinoma: a tale of multiple confounders L Ielasi, F Tovoli, M Tonnini, R Tortora, G Magini, R Sacco, T Pressiani, ... Cancers 13 (24), 6376, 2021 | 15 | 2021 |
| Comparison of prognostic scores in patients with hepatocellular carcinoma treated with sorafenib V Sansone, F Tovoli, A Casadei-Gardini, GG Di Costanzo, G Magini, ... Clinical and Translational Gastroenterology 12 (1), e00286, 2021 | 15 | 2021 |
| Donafenib in hepatocellular carcinoma. R Chen, L Ielasi, A di Carlo, F Tovoli Drugs of Today (Barcelona, Spain: 1998) 59 (2), 83-90, 2023 | 14 | 2023 |
| Lenvatinib mesylate to treat hepatocellular carcinoma. L Ielasi, F Tovoli, F Piscaglia Drugs of Today (Barcelona, Spain: 1998) 55 (5), 305-313, 2019 | 14 | 2019 |
| An update of treatments of hepatocellular carcinoma in patients refractory to sorafenib. L Ielasi, V Sansone, A Granito, F Benevento, S De Lorenzo, F Tovoli Drugs of Today (Barcelona, Spain: 1998) 54 (10), 615-627, 2018 | 9 | 2018 |
| Direct oral anticoagulants for the treatment of splanchnic vein thrombosis: A state of art G Monaco, L Bucherini, B Stefanini, F Piscaglia, FG Foschi, L Ielasi World Journal of Gastroenterology 29 (33), 4962, 2023 | 8 | 2023 |
| Outcomes of sorafenib for recurrent hepatocellular carcinoma after liver transplantation in the era of combined and sequential treatments F Tovoli, DP Pallotta, V Sansone, M Iavarone, M De Giorgio, L Ielasi, ... Transplantation 107 (1), 156-161, 2023 | 8 | 2023 |
| Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib M Rimini, C Yoo, S Lonardi, G Masi, F Piscaglia, HD Kim, MD Rizzato, ... Hepatology Research 51 (7), 796-802, 2021 | 6 | 2021 |
| Long-lasting remission in a metastatic hepatocellular carcinoma patient after combined regorafenib therapy and surgery E Goio, L Ielasi, F Benevento, M Renzulli, F Tovoli Hepatic Oncology 7 (3), HEP24, 2020 | 4 | 2020 |
| Intermediate-stage hepatocellular carcinoma: refining substaging or shifting paradigm? B Stefanini, L Ielasi, DP Pallotta, S Penazza, M Marseglia, F Piscaglia Journal of Liver Cancer 24 (1), 23-32, 2024 | 3 | 2024 |
| Current guidelines for diagnosis and management of hepatic involvement in hereditary hemorrhagic teleangiectasia L Ielasi, M Tonnini, F Piscaglia, I Serio World Journal of Hepatology 15 (5), 675, 2023 | 3 | 2023 |
| Prognostic impact of metastatic site in patients receiving first-line sorafenib therapy for advanced hepatocellular carcinoma L Ielasi, F Tovoli, M Tonnini, B Stefanini, R Tortora, G Magini, R Sacco, ... Cancers 15 (5), 1523, 2023 | 3 | 2023 |
| Comparative analysis of subclassification systems in patients with intermediate-stage hepatocellular carcinoma (Barcelona Clinic Liver Classification B) receiving systemic therapy L Ielasi, B Stefanini, F Conti, M Tonnini, R Tortora, G Magini, R Sacco, ... Current Oncology 31 (1), 547-557, 2024 | 2 | 2024 |
| Absence of Viral Replication Is Associated With Improved Outcome in Anti‐HCV‐Positive Patients With Hepatocellular Carcinoma EG Giannini, A Pasta, MC Plaz Torres, G Pieri, G Cabibbo, A Sangiovanni, ... Liver International 45 (2), e16185, 2025 | 1 | 2025 |
